1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Drug Importation Blocked But Not Forgotten As User Fee Bill Clears Senate Cmte

 
• By Derrick Gingery

Amendment from Sen. Sanders was tabled in part to avoid adding a controversial provision that could slow the bill's passage, but may be debated during upcoming drug costs hearing.

PackedImportedDrugs_1200

Controversial drug importation legislation likely will not be attached to the FDA user fee reauthorization, but has gained support and may be considered during a congressional hearing to deal with drug costs.

It was the only issue debated during the May 11 Senate Health, Education, Labor and Pensions Committee mark-up of the FDA Reauthorization Act that potentially could slow or stop the bill from full Senate approval

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

Pink Sheet Podcast: A New Director For US FDA’s Biologics Center, Guidance Production Slowdowns

 
• By Derrick Gingery, Sue Sutter, and Nielsen Hobbs

Pink Sheet editors discuss the appointment of Vinay Prasad as the new director of the Center for Biologics Evaluation and Research and revelations that FDA layoffs now are hindering development of guidance documents.

US FDA Restoring Some Library Resources

 
• By Sue Sutter and Derrick Gingery

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals, and laid off librarians have not been reinstated.

US FDA Advisory Committee Misperceptions Abound … At HHS

 
• By Michael McCaughan

HHS Secretary Robert F. Kennedy Jr. regularly decries the “conflicts of interest” he believes abound in advisory committees, but his concerns, as well as a recent “policy directive” eliminating industry representatives, seem driven by a misunderstanding of the panels’ jobs.

US FDA Layoffs Hit Conflict-Of-Interest Screening For ODAC Meeting

 
• By Sue Sutter and Derrick Gingery

Screening for conflicts and finding the right expertise for a two-day Oncologic Drugs Advisory Committee meeting on four products has been complicated by the Trump Administration’s initial communications freeze and subsequent layoffs in CDER.

More from Agency Leadership